3E Bioventures
Venture Capital
Active
Palo Alto, United States
56
30M
40
6.22
12
0.27
1
- Areas of investment
Summary
The venture was found in Asia in China. The main department of described VC is located in the Beijing.
Among the most successful fund investment fields, there are Genetics, Clinical Trials. Among the most popular portfolio startups of the fund, we may highlight Ansun BioPharma, Profusa, Apexigen. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the 3E Bioventures, startups are often financed by SDIC Venture Capital, BioVeda China Fund, Morningside Group. The meaningful sponsors for the fund in investment in the same round are CMB International Capital Corporation, WuXi Healthcare Ventures, Shangbay Capital. In the next rounds fund is usually obtained by WuXi Healthcare Ventures, VT Ventures, Tasly Pharmaceutical.
Speaking about the real fund results, this VC is 9 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2018. The fund is constantly included in 2-6 deals per year. The common things for fund are deals in the range of 10 - 50 millions dollars.
Investor highlights
- Industry focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 56
- Lead investments
- 12
- Exits
- 1
- Rounds per year
- 6.22
- Follow on index
- 0.27
- Investments by industry
- Health Care (36)
- Biotechnology (35)
- Medical (24)
- Medical Device (14)
- Biopharma (13) Show 25 more
- Investments by region
-
- United States (28)
- China (24)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Avg. valuation at time of investment
- 20M
- Group Appearance index
- 0.89
- Avg. company exit year
- 20
- Avg. multiplicator
- 5.74
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Dermaliq Therapeutics | 21 Jan 2022 | Fitness, Health Care, Wellness, Pharmaceutical | Early Stage Venture | 15M | United States, Delaware, Wilmington |
| Zhengli Technology | 29 Dec 2021 | Health Care, Manufacturing, Medical Device, Medical, Dental | Late Stage Venture | 15M | Tianjin, Guangdong, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.